<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2020-03-26">26 March 2020</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chen-Yu</forename><surname>Huang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Taipei Veterans General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Min</forename><surname>Cheng</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Taipei Veterans General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Na-Rong</forename><surname>Lee</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Taipei Veterans General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Nursing, Taipei Veterans General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hsin-Yi</forename><surname>Huang</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Biostatics Task Force, Taipei Veterans General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wen-Ling</forename><surname>Lee</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Medicine, Cheng-Hsin General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Department of Nursing, Oriental Institute of Technology</orgName>
								<address>
									<addrLine>New Taipei City 220</addrLine>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wen-Hsun</forename><surname>Chang</surname></persName>
							<email>whchang818@gmail.com</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Taipei Veterans General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Nursing, Taipei Veterans General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peng-Hui</forename><surname>Wang</surname></persName>
							<email>phwang@vghtpe.gov.tw</email>
							<idno type="ORCID">0000-0002-6048-8541</idno>
							<affiliation key="aff0">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Taipei Veterans General Hospital</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<postCode>112</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Department of Medical Research</orgName>
								<orgName type="department" key="dep2">Medical University Hospital</orgName>
								<address>
									<postCode>440</postCode>
									<settlement>Taichung</settlement>
									<country>China, Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Female Cancer Foundation</orgName>
								<address>
									<postCode>104</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2020-03-26">26 March 2020</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.3390/ijerph17072213</idno>
					<note type="submission">Received: 12 February 2020; Accepted: 24 March 2020;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>dose-dense weekly paclitaxel</term>
					<term>epithelial tubo-ovarian cancer</term>
					<term>FIGO stage IIIC</term>
					<term>primary peritoneal serous carcinoma</term>
					<term>triweekly carboplatin</term>
					<term>triweekly cisplatin</term>
				</keywords>
			</textClass>
			<abstract>
				<p>The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m 2), but it would be interesting to know what is the difference between combination of triweekly cisplatin (20 mg/m 2) or triweekly carboplatin (carboplatin area under the curve 5-7 mg/mL per min [AUC 5-7]) in the dose-dense paclitaxel regimen. Therefore, we compared the outcomes of women with Gynecology and Obstetrics (FIGO) stage IIIC ETOC and PPSC treated with PCS and a subsequent combination of dose-dense weekly paclitaxel and triweekly cisplatin (paclitaxel-cisplatin) or triweekly carboplatin using AUC 5 (paclitaxel-carboplatin). Between January 2010 and December 2016, 40 women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC EOC, FTC, or PPSC were enrolled, including 18 treated with paclitaxel-cisplatin and the remaining 22 treated with paclitaxel-carboplatin. There were no statistically significant differences in disease characteristics of patients between two groups. Outcomes in paclitaxel-cisplatin group seemed to be little better than those in paclitaxel-carboplatin (median progression-free survival [PFS] 30 versus 25 months as well as median overall survival [OS] 58.5 versus 55.0 months); however, neither reached a statistically significant difference. In terms of adverse events (AEs), patients in paclitaxel-carboplatin group had more AEs, with a higher risk of neutropenia and grade 3/4 neutropenia, and the need for a longer period to complete the front-line chemotherapy, and the latter was associated with worse outcome for patients. We found that a period between the first-time chemotherapy to the last dose (6 cycles) of chemotherapy &gt;21 weeks was associated with a worse prognosis in patients compared to that ≤21 weeks, with hazard ratio (HR) of 81.24 for PFS and 9.57 for OS. As predicted, suboptimal debulking surgery (&gt;1 cm) also contributed to a worse outcome than optimal debulking surgery (≤1 cm) with HR of 14.38 for PFS and 11.83 for OS. Based on the aforementioned findings, both regimens were feasible and effective, but maximal efforts should be made to achieve optimal debulking</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>Epithelial tubo-ovarian cancer (ETOC) is the deadliest cancer among women, placing with fourth place of all the fetal diseases among women and ranking seventh of most common cancers in women's cancer and women's cancer-related deaths in Taiwan and globally in 2018 <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>. Serous-type is the most common subtype among EOCs in general; however, endometriosis-associated EOCs, such as clear cell type or endometrioid type are relatively common in certain populations, including Taiwan and Japan <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>. Clinically, the serous-type EOC and primary peritoneal serous carcinoma (PPSC) and primary Fallopian tube cancer (PFTC) are often considered the same group disease, based on the similar clinical behavior and possibly sharing the similar pathogenesis <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>. In 1996, McGuire and colleagues conducted a clinical trial to set up the standard therapy for patients with ETOC, including primary debulking surgery (PDS), also called primary cytoreductive surgery (PCS) plus adjuvant triweekly paclitaxel and cisplatin therapy <ref type="bibr" target="#b18">[19]</ref>. The following studies have confirmed the superiority of survival benefits using paclitaxel into cisplatin-based regimens in place of cyclophosphamide for the treatment of patients with ETOC and PPSC <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref>. Additionally, carboplatin in place of cisplatin in this combination has statistically significantly reduced the cisplatin-related potential toxicity of neural and renal systems and ameliorated the cisplatin-related high emetic effects <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1.">Current Standard of Treatment</head><p>According to the National Comprehensive Cancer Network (NCCN) guideless version 1.2020 Ovarian Cancer/Fallopian Tube Cancer/Primary Perineal Cancer, principles of systemic therapy regimens for advanced-stage high-grade serous ETOC and PPSC included three parts <ref type="bibr" target="#b25">[26]</ref>. Preferred regimens <ref type="bibr" target="#b25">[26]</ref> include (1) the combination of intravenous (IV) paclitaxel 175 mg/m 2 and IV carboplatin area under the curve ranging from 5 mg/mL per min (AUC 5) to 6 mg/mL per min (AUC 6) every three weeks (Q3W, also called triweekly) for 3-6 cycles <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref>; (2) IV paclitaxel 175 mg/m 2 day 1 followed by IV carboplatin AUC 6 Day 1 and bevacizumab 7.5 mg/kg Day 1 of cycle 1 Q3W for 5-6 cycles plus additional 12 cycles of bevacizumab Q3W for maintenance therapy; (3) IV paclitaxel 175 mg/m 2 followed by IV carboplatin AUC 6 Day 1 Q3W for 6 cycles with 15 mg/kg bevacizumab added starting on Day 1 of cycle 2, Q3W for up to a total of 22 cycles <ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref>.</p><p>Other recommended regimens <ref type="bibr" target="#b25">[26]</ref> include the following four regimens, such as (1) IV paclitaxel 60 mg/m 2 followed by IV carboplatin AUC 2 every week (weekly) <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref>, (2) IV docetaxel 60-75 mg/m 2 and IV carboplatin AUC 5-6 Q3W <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b34">35]</ref>, (3) IV carboplatin AUC 5 and IV pegylated liposomal doxorubicin 30 mg/m 2 every four weeks (Q4W) <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref>, and (4) IV paclitaxel 80 mg/m 2 weekly and IV carboplatin AUC 5 to AUC 7 triweekly <ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref>.</p><p>The final part-which is especially useful in certain circumstances, such as in patients having optimally PCS stage II-IV diseases <ref type="bibr" target="#b25">[26]</ref>-is the combination of IV paclitaxel 135 mg/m 2 on Day 1, intraperitoneal (IP) cisplatin 75-100 mg/m 2 on Day 2, and IV paclitaxel 60 mg/m 2 on Day 8 Q3W for 6 cycles <ref type="bibr" target="#b42">[43,</ref><ref type="bibr" target="#b43">44]</ref>. Although there are so many recommendations available as shown above, now, the most frequently acceptable standard chemotherapy for ETOC and PPSC is still the use of combination of triweekly carboplatin and paclitaxel <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref>.</p><p>However, the prognosis of patients with ETOC and PPSC is still disappointing, because of vague or free symptoms of patients, often misdiagnosed as less deadly gastro-enteral tract problems, and the absence of effective screening programs, and, in addition, its heterogeneous nature and different clinical development, accounting for late diagnosis in its advanced stages <ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref>. All result in a therapeutic challenge, contributing to low cure rate and high mortality rate, <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref>. A median progression-free survival (PFS) is 16-21 months and an overall survival (OS) is 32-57 months <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref>. Therefore, an improvement of therapeutic effect as well as a prolongation of PFS and/or OS is urgently needed.</p><p>Based on the relative worse prognosis of advanced-stage ETOC and PPSC, many new modalities and strategies have been recently developed <ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref><ref type="bibr" target="#b57">[58]</ref><ref type="bibr" target="#b58">[59]</ref>. Although some of them have been already recommended by updated NCCN guidelines for ETOC and PPSC treatment <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b25">26]</ref>, they are not widely used in the routine clinical practice <ref type="bibr" target="#b59">[60]</ref>. Among these, induction chemotherapy (neoadjuvant chemotherapy-NACT) using either standard form of paclitaxel and carboplatin or its modification form, including dose-dense or high-dose chemotherapy, and in additional adding bevacizumab, has become more and more popular, especially for those patients who are not candidates for immediate PCS <ref type="bibr" target="#b60">[61]</ref><ref type="bibr" target="#b61">[62]</ref><ref type="bibr" target="#b62">[63]</ref><ref type="bibr" target="#b63">[64]</ref><ref type="bibr" target="#b64">[65]</ref><ref type="bibr" target="#b65">[66]</ref><ref type="bibr" target="#b66">[67]</ref><ref type="bibr" target="#b67">[68]</ref><ref type="bibr" target="#b68">[69]</ref>.</p><p>In addition, the changed delivery route or warm-up of chemotherapy agents (IP administration or IP hyperthermia therapy) has been also accepted in the certain clinical situations <ref type="bibr" target="#b42">[43,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b69">[70]</ref><ref type="bibr" target="#b70">[71]</ref><ref type="bibr" target="#b71">[72]</ref><ref type="bibr" target="#b72">[73]</ref><ref type="bibr" target="#b73">[74]</ref><ref type="bibr" target="#b74">[75]</ref>. Moreover, advancing drug development, including poly(adenosine diphosphate (ADP)-ribose) polymerase inhibitors (PARPi) as well as small molecules targeting various kinds of signaling pathway has shown the dramatic improvement in ETOC and PPSC treatment <ref type="bibr" target="#b75">[76]</ref><ref type="bibr" target="#b76">[77]</ref><ref type="bibr" target="#b77">[78]</ref><ref type="bibr" target="#b78">[79]</ref><ref type="bibr" target="#b79">[80]</ref><ref type="bibr" target="#b80">[81]</ref><ref type="bibr" target="#b81">[82]</ref><ref type="bibr" target="#b82">[83]</ref><ref type="bibr" target="#b83">[84]</ref><ref type="bibr" target="#b84">[85]</ref><ref type="bibr" target="#b86">[86]</ref><ref type="bibr" target="#b87">[87]</ref>. Finally, immune checkpoint inhibitors or immune system modulators has also provided a chance for ETOC and PPSC patients, although the therapeutic effect is debated <ref type="bibr" target="#b88">[88,</ref><ref type="bibr" target="#b89">89]</ref>. However, there is no doubt that the high cost of the aforementioned new therapeutic approaches will limit the clinical use in routine <ref type="bibr" target="#b90">[90]</ref>, and in addition, the compliance may be compromised by the requirement of maintenance or continuous long-term therapy in some drugs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2.">Gap in Knowledge of Current Standard of Therapy</head><p>Based on the negative impact on the high cost of many targeted therapies and the poor compliance of long-term maintenance therapy in certain population, as well as no differences or the improvement of clinical outcomes in additional drugs added to platinum/taxane combination or the use of different platinum doublets <ref type="bibr" target="#b91">[91]</ref>, dose-dense platinum/taxane might be a good alternative, due to the similar duration of completing therapy and acceptable cost expense. In addition, some evidence also favored this regimen as a feasible front-line chemotherapy for patients after PCS, based on the possible PFS benefits and considerably robust cost-effectiveness <ref type="bibr" target="#b92">[92,</ref><ref type="bibr" target="#b93">93]</ref>.</p><p>In theory, the maximal tolerated doses of chemotherapy may yield the highest cytotoxicity to tumors, with subsequent higher cure rates <ref type="bibr" target="#b94">[94]</ref>. However, such treatment may need a longer treatment-free period to wait normal host cells for recovery <ref type="bibr" target="#b94">[94]</ref>. Among these, hematopoietic progenitors might be the best example <ref type="bibr" target="#b94">[94]</ref>. Without this treatment-free period, some catastrophic and life-threatened conditions might occur. During the holiday of drug, cancer cells and cells in the tumor microenvironment may also re-grow, possibly resultant development of aggressive behavior and chemo-resistance clone of tumor cells. All decided a rule of thumb to design most chemotherapy combinations to be repeated every three or four weeks <ref type="bibr" target="#b95">[95]</ref>. The triweekly carboplatin plus paclitaxel regimen is just followed by the aforementioned rule, and this protocol is still one of the best-known and golden-standard regimens in the management of EOC patients after PCS.</p><p>However, this "golden-standard" therapy only provides the relatively short PFS and unsatisfactory OS in these advanced-stage EOC patients, making the urgent needs of application of new strategies to improve therapeutic outcome and prolong the patients' life. Since the use of 3-drug combinations and maintenance chemotherapy after the front-line chemotherapy is not recommended because of the absence of survival benefits but significantly increased adverse events (AEs) and possibly compromised quality of life <ref type="bibr" target="#b49">[50,</ref><ref type="bibr" target="#b50">51,</ref><ref type="bibr" target="#b58">59]</ref>, another strategy without the involving adding any new agents or targeted therapy is pursued <ref type="bibr" target="#b44">[45]</ref>. Therefore, if single dose of treatment is decreased in their dosage, the holiday of drugs can be shortened. A dose-dense weekly prescription of drugs may fulfill the aforementioned requirement.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3.">Rationale of Dose-Dense Therapy</head><p>Dose-dense weekly chemotherapy is based on the concept of shortening the timing of recycling by Goldie-Coldman's hypothesis and the Norton-Simon model <ref type="bibr" target="#b96">[96]</ref><ref type="bibr" target="#b97">[97]</ref><ref type="bibr" target="#b98">[98]</ref>, providing the rationale, such as a reducing interval between treatment, an increasing duration of chemotherapy exposure, and an increasing dose-intensity or dose-density of cytotoxic agents, and offering a chance that tumor regrowth could be decreased by this approach <ref type="bibr" target="#b99">[99]</ref><ref type="bibr" target="#b100">[100]</ref><ref type="bibr" target="#b101">[101]</ref><ref type="bibr" target="#b102">[102]</ref>. In addition, dose-dense chemotherapy can not only preserve the immune system but also promote the treatment-mediated tumor-specific immunity, especially the antitumor kill cluster of differentiation 8+ (CD8+) T-cell response <ref type="bibr" target="#b103">[103]</ref>. Therefore, hematological markers have been evaluated to try to establish their predictive value <ref type="bibr" target="#b104">[104]</ref><ref type="bibr" target="#b105">[105]</ref><ref type="bibr" target="#b106">[106]</ref><ref type="bibr" target="#b107">[107]</ref>. Dose intensity strategies include increasing the dose per cycle, decreasing the cycle interval (dose densification) and decreasing the interval plus increasing the dose <ref type="bibr" target="#b108">[108]</ref>. However, the latter two strategies involved shortening the gap between chemotherapy, which has proven decisive in some neoplasms such as breast cancer <ref type="bibr" target="#b99">[99]</ref>, and, of most importance, this more frequent administration of cytotoxic agents within short intervals has also decreased the chemotherapy-related death associated with the use of massive doses, such as infection or sepsis caused by severe neutropenia or spontaneous hemorrhage caused by severe thrombocytopenia <ref type="bibr" target="#b48">[49]</ref>.</p><p>Dr. Muggia proposed a very interesting hypothesis to show the potential benefits of dose-dense sequential treatment designs for first line, such as an initial dose-dense cisplatin and following dose-dense paclitaxel based on unpublished data from GOG-132 and ICON3 (Gynecologic Cancer InterGroup (GCIG) International Collaboration on Ovarian Neoplasms 3) in 2003 <ref type="bibr" target="#b109">[109]</ref>. In the next year (2004), the same author found that increasing the dose of cisplatin above a certain threshold is not recommended in EOC patients because the greater toxicity with higher dose of cisplatin was found <ref type="bibr" target="#b110">[110]</ref>, although some studies did not support a significant increase toxicity after weekly dose-dense cisplatin treatment (median dose intensity with 32 or 45 mg/m 2 /week) <ref type="bibr" target="#b108">[108]</ref>. However, the therapeutic effect of dose-dense platinum is still controversial. Some are in favor <ref type="bibr" target="#b111">[111,</ref><ref type="bibr" target="#b112">112]</ref>, but many are against the resultant benefits of dose-dense platinum <ref type="bibr" target="#b108">[108,</ref><ref type="bibr" target="#b113">[113]</ref><ref type="bibr" target="#b115">[114]</ref><ref type="bibr" target="#b116">[115]</ref><ref type="bibr" target="#b117">[116]</ref>. Biweekly dose-dense carboplatin (AUC5) combined with paclitaxel (175 mg/m 2 ) is not feasible based on dose-limiting toxicity, even though GCSF was used for support <ref type="bibr" target="#b117">[116]</ref>. Previous studies that the main determinant of dose-dense treatment response was not achieved by the relative dose intensity of platinum itself <ref type="bibr" target="#b108">[108]</ref>. Indeed, one report showed that the administration of dose up to cisplatin of 25 mg/m 2 /week might reach the plateau of dose-response curve <ref type="bibr" target="#b113">[113]</ref>.</p><p>By contrast, the toxicity of dose-dense taxane seemed to be well tolerated because of absence of relevant toxicity <ref type="bibr" target="#b94">[94]</ref>. A pharmacokinetic study revealed that paclitaxel can be administered weekly at doses of 110 mg/m 2 without interruption, while neutropenia precluded scheduled administration of doses ≥ 130 mg/m 2 <ref type="bibr" target="#b94">[94,</ref><ref type="bibr" target="#b118">117]</ref>. In theory, weekly dose-dense paclitaxel provided the better cytotoxicity to tumors, through more sustained exposure, limiting the emergence of tumors resistant to chemotherapy, enhancing the apoptotic and antiangiogenic effect, and improving the therapeutic index <ref type="bibr" target="#b94">[94,</ref><ref type="bibr" target="#b119">[118]</ref><ref type="bibr" target="#b120">[119]</ref><ref type="bibr" target="#b121">[120]</ref>, although the single use of dose-dense paclitaxel for the first-line chemotherapy treatment of patients with ETOC seemed to be not approved by clinical trials <ref type="bibr" target="#b109">[109,</ref><ref type="bibr" target="#b110">110]</ref>.</p><p>Therefore, the application of a combination of taxane and platinum in ETOC has been conducted. In the management of all chemosensitive epithelial cancers, combination chemotherapy treatment has provided significant survival benefits compared to single agent chemotherapy when applied as initial therapy, and there is no doubt that the treatment of ETOC is similar in this regard <ref type="bibr" target="#b122">[121]</ref>. Studies showed that combination of taxane and platinum compound appears both to attenuate the toxicity of the platinum compound and to facilitate the delivery of full dose on schedule and this full dose on schedule showed the strong correlation with patient outcomes <ref type="bibr" target="#b110">[110]</ref>. Since both platinum and paclitaxel are the essential cytotoxic agents in ETOC patients after PCS, either any one or both can be administered as dose-dense protocol. Furthermore, dose-dense can be classified according to the types, including semiweekly dose-dense, in which paclitaxel was given weekly and carboplatin was given triweekly, and weekly dose dense, in which both paclitaxel and carboplatin were given weekly <ref type="bibr" target="#b46">[47]</ref>. An accumulation dose of paclitaxel is 240-270 mg/m 2 with separating into 80-90 mg/m 2 per week compared to a single use of 175-180 mg/m 2 every three weeks. By contrast, the dosage of carboplatin seems to be consistent with accumulation dose as AUC 5-7, regardless of administration triweekly (a single use of AUC 5-7) or weekly (AUC 2).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.4.">Previous Studies for Dose-Dense Therapy</head><p>Since the rational of dose-dense therapy supports the potential benefits for patients with advanced stage ETOC and PPSC, at least four large randomized clinical trials were conducted to test the hypothesis <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref>. The Japanese Gynecologic Oncology Group (JGOG) 3016, named as JGOG 3016, provided a strong evidence to show the survival benefits in the combination regimen including dose-dense weekly paclitaxel (80 mg/m 2 ) and triweekly carboplatin (AUC 6), which not only offered a longer PFS but also a significantly prolonged OS compared to those in a standard triweekly combination of paclitaxel and carboplatin treatment <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref>.</p><p>By contrast, this promising result was not reproducible in three other trials conducted in Western countries. The results of an NRG Oncology (the National Cancer Institute Cooperative Group Program plus the Radiation Therapy Oncology plus Gynecology Oncology Group)/GOG Study showed the similar PFS and OS in dose-dense regimen with adding 15 mg/kg bevacizumab treatment compared to the standard triweekly combination therapy <ref type="bibr" target="#b71">[72]</ref>. MITO-7 (Multicentre Italian Trials in Ovarian cancer 7) showed that there was no statistically significant difference of median PFS between dose-dense weekly combination and standard triweekly combination therapy <ref type="bibr" target="#b31">[32]</ref>. GOG-0262 showed no statistical difference of the median PFS between dose-dense weekly paclitaxel and triweekly carboplatin with/without adding 15 mg/kg bevacizumab treatment, respectively, and standard triweekly combination therapy <ref type="bibr" target="#b74">[75]</ref>. The results from an ICON8 showed that the restricted mean PFS was not statistically significant different among the three groups (dose-dense or standard groups) <ref type="bibr" target="#b32">[33]</ref>.</p><p>A recent meta-analysis conducted by Marchetti and colleagues further updated these four randomized controlled trials containing 3698 patients, and found that dose-dense chemotherapy did not have a statistically significant benefit of PFS (HR 0.92, 95% CI 0.81-1.04) <ref type="bibr" target="#b46">[47]</ref>. Additionally, the results were not changed with HR 1.01 (95% CI 0.93-1.10) and 0.82 (95% CI 0.63-1.08), respectively, even though the analysis was limited to both weekly and semi-weekly dose-dense data <ref type="bibr" target="#b46">[47]</ref>. Therefore, the authors believed that conventional triweekly combination chemotherapy is still one of the golden-standard treatments of patients with advanced stage ETOC <ref type="bibr" target="#b46">[47]</ref>.</p><p>Why are the survival benefits only apparent in certain populations, such as Japanese or others? Although the real reasons associated with conflicted results are uncertain, genomic background of race, tumor heterogeneity, administration schedule, cisplatin or carboplatin, and the duration to complete postoperative adjuvant chemotherapy may all be attributable. Among these, we believe that platinum compound may play a certain role in the discrepancy.</p><p>In order to evaluate the effects and safety of dose-dense of paclitaxel combining with either cisplatin or carboplatin, the following retrospective study was conducted. Patients with FIGO IIIC serous-type ETOC and PPSC treated either with triweekly cisplatin (20 mg/m 2 ) plus dose-dense weekly paclitaxel (80 mg/m 2 ) or triweekly carboplatin (AUC 5) plus dose-dense weekly paclitaxel (80 mg/m 2 ) as postoperative adjuvant chemotherapy after PCS were retrospectively reviewed. However, nearly all dose-dense paclitaxel-platinum combination chemotherapy regimens used as the front-line postoperative adjuvant therapy are focused on the dose-dense paclitaxel, without consideration of either the platinum compounds or the dose-dense agents.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Patient Population</head><p>After institutional review board approval (VGHIRB 2019-07-039BC), all patients between January 2010 and December 2016 who fulfilled the following inclusion (International Federation of Gynecology and Obstetrics (FIGO) stage IIIC histologically confirmed high-grade serous-type ETOC and PPSC, an initial PCS, a total of six cycles of weekly paclitaxel [80 mg/m 2 ] plus either triweekly cisplatin [20 mg/m 2 ] or triweekly carboplatin [AUC 5] regimen) and exclusion (NACT, other newly diagnosed cancer, previous chemotherapy, or radiotherapy in the past two years; incomplete chemotherapy or the delayed of the first course chemotherapy (&gt;7 days after PCS), simultaneous use of other antineoplastic agents, antiangiogenic agents, or targeted therapy) criteria were identified from our gynecologic oncology registry. Since both cisplatin and carboplatin are available in our department, the selection of cisplatin or carboplatin was based on the patient's will after shared decision making.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Treatment</head><p>All patients underwent PCS initially and then were treated with weekly paclitaxel (80 mg/m 2 ) plus either triweekly cisplatin (20 mg/m 2 ) or triweekly carboplatin (AUC 5). Paclitaxel was administered over 2 h intravenously on days 1, 8, and 15, and either cisplatin for 1 h or carboplatin for 1 h on day 1 was infused intravenously. Premedication including dexamethasone (20 mg), 2000 ml of normal saline, and palonosetron (250 ug) was prescribed intravenously during the chemotherapy therapy day. When grade 3/4 neutropenia occurred, the patients were treated with granulocyte colony-stimulating factor (GCSF) for three days before chemotherapy. However, treatment was delayed if febrile neutropenia or grade 3/4 neutropenia without correction was noted. If a three-fold increase in liver enzymes of patients was detected, paclitaxel (60 mg/m 2 ) was used. The cisplatin dose was decreased to half dosage if the estimated glomerular filtration rate (eGFR) was decreased to 45-60 ml/min, which was calculated using the Cockcroft-Gault formula <ref type="bibr" target="#b123">[122]</ref><ref type="bibr" target="#b124">[123]</ref><ref type="bibr" target="#b125">[124]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Assessments</head><p>The first course chemotherapy was prescribed within one week after PCS. The clinical symptoms or signs-including the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0Adverse effects (AEs)-were used to evaluate the severity of adverse events before every cycle of treatment <ref type="bibr" target="#b126">[125,</ref><ref type="bibr" target="#b127">126]</ref>. During the follow-up, the patients received both image evaluation, such as ultrasound, computed tomography, or magnetic resonance imaging and biochemical markers, such as CA-125 (the abbreviation of cancer antigen 125, carcinoma antigen 125, or carbohydrate antigen 125) examinations. The evaluation of image finding was based on Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 <ref type="bibr" target="#b128">[127]</ref><ref type="bibr" target="#b129">[128]</ref><ref type="bibr" target="#b130">[129]</ref>. Criteria of progression or recurrence were based on findings of clinical symptoms or signs accompanied with image findings and tumor markers described elsewhere <ref type="bibr" target="#b40">[41,</ref><ref type="bibr" target="#b131">130,</ref><ref type="bibr" target="#b132">131]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Statistical Analysis</head><p>The primary endpoint was PFS, defined as the time from the date patients first underwent PCS to the earliest date of disease progression, death from any cause, or the date of the last known follow-up. The secondary endpoint was OS, defined as the time from the date patients first underwent PCS to the date of death from any cause or the date of the last known follow-up. The Kaplan-Meier method was used to generate survival curves, and the log-rank test was used to detect the differences between survival curves. Prognostic factors for PFS or OS were evaluated using Cox proportional hazard methods. Multivariate analysis using Cox stepwise forward regression was conducted for the covariates selected in univariate analysis. A p value &lt;0.05 was considered to be statistically significant. All statistical analyses were conducted with SAS version 9.3 (SAS Institute, Cary, NC) and Stata Statistical Software, version 12.0 (Stata Corporation, College Station, TX).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Clinical Characteristics and Pathological Status</head><p>A total of 40 women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC ETOC or PPSC were analyzed, including 18 treated with paclitaxel-cisplatin and the remaining 22 treated with paclitaxel-carboplatin. <ref type="table" target="#tab_0">Table 1</ref> summarizes the characteristics of patients in each group. The mean age of the whole population was 59 years. Optimal PCS was achieved in 55% in overall, and 54.5% and 55.6% in the paclitaxel-carboplatin and paclitaxel-cisplatin groups, respectively. Patients in the paclitaxel-carboplatin group had a higher risk of a prolonged time to finish 6 cycles of the front-line chemotherapy after PCS than those in paclitaxel-cisplatin group (45.5% versus 11.1%, p = 0.018), which reached the statistically significant difference. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Adverse Events (AEs)</head><p>Adverse events (AEs) are listed in <ref type="table">Table 2</ref>. In the current study, no treatment-related death was found. The most common all-grade AEs in the entire cohort included anemia, nausea, neutropenia, and peripheral neuropathy. However, the occurrence of each AE was different in both groups. Patients who were treated with the paclitaxel-carboplatin regimen had a higher risk of development of neutropenia than those with the paclitaxel-cisplatin regimen. In addition, grade 3/4 neutropenia occurred more frequently in patients treated with the paclitaxel-carboplatin regimen compared to that in patients with the paclitaxel-cisplatin regimen. Both reached the statistically significant difference. In current study, cisplatin-related AEs, such as renal toxicity, neurotoxicity, nausea, or vomiting were mild or absent, as shown in <ref type="table">Table 2</ref>. <ref type="table">Table 2</ref>. Adverse events the patients with FIGO IIIC serous type epithelial tubo-ovarian cancer, or primary peritoneal carcinoma treated with weekly paclitaxel (80 mg/m 2 ) plus either carboplatin (AUC 5) or cisplatin (20 mg/m 2 ) combination chemotherapy triweekly.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Events</head><p>Any grade, n (%) </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Outcomes</head><p>During the whole study period with a median follow-up time of 55 months (at the time of the data cutoff on 30 June 2019), disease progression and/or disease-related death occurred in 23 patients (57.5%). As was presented in <ref type="figure" target="#fig_0">Figure 1</ref>, the median PFS was 25.0 months in patients treated with the paclitaxel-carboplatin regimen, and 30.0 months in patients treated with the paclitaxel-cisplatin regimen, without a statistically significant difference. The median OS was 55.0 months and 58.5 months in patients treated with paclitaxel-carboplatin and paclitaxel-cisplatin regimens, respectively <ref type="figure" target="#fig_2">(Figure 2</ref>). There was also no statistically significant difference between the two groups. <ref type="table">Table 2</ref>. Adverse events the patients with FIGO IIIC serous type epithelial tubo-ovarian cancer, or primary peritoneal carcinoma treated with weekly paclitaxel (80 mg/m 2 ) plus either carboplatin (AUC 5) or cisplatin (20mg/m 2 ) combination chemotherapy triweekly. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Events Any grade, n (%) Grade 3/4, n (%)</head><note type="other">CARBO</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Outcomes</head><p>During the whole study period with a median follow-up time of 55 months (at the time of the data cutoff on 30 June 2019), disease progression and/or disease-related death occurred in 23 patients (57.5%). As was presented in <ref type="figure" target="#fig_0">Figure 1</ref>, the median PFS was 25.0 months in patients treated with the paclitaxel-carboplatin regimen, and 30.0 months in patients treated with the paclitaxel-cisplatin regimen, without a statistically significant difference. The median OS was 55.0 months and 58.5 months in patients treated with paclitaxel-carboplatin and paclitaxel-cisplatin regimens, respectively <ref type="figure" target="#fig_2">(Figure 2</ref>). There was also no statistically significant difference between the two groups.   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Prognostic Factors</head><p>To identify the prognostic factors for disease progression (PFS), a univariate analysis of clinic-pathologic factors showed that residual tumors more than 1 cm in size and the prolonged completion of postoperative adjuvant chemotherapy were associated with worse prognosis <ref type="table" target="#tab_3">(Table  3</ref>). Both these factors were also independent risk factors when using the multivariate analysis model.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Prognostic Factors</head><p>To identify the prognostic factors for disease progression (PFS), a univariate analysis of clinic-pathologic factors showed that residual tumors more than 1 cm in size and the prolonged completion of postoperative adjuvant chemotherapy were associated with worse prognosis <ref type="table" target="#tab_3">(Table 3)</ref>. Both these factors were also independent risk factors when using the multivariate analysis model. <ref type="table" target="#tab_3">Table 3</ref>. Association between baseline characteristics and progression-free survival. Further evaluation was performed to analyze the prognostic factors associated with overall survival and the results showed that optimal debulking surgery was the most important independent prognostic factor to predict better outcomes in patients with FIGO IIIC ETOC and PPSC. However, the on-schedule administration of postoperative adjuvant chemotherapy regardless, in-time and on-time chemotherapy was also a very important predictor in those patients who had a better chance for prolonged OS <ref type="table" target="#tab_5">(Table 4)</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Parameters</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.">Main Findings</head><p>The main findings of the current study showed that both regimens could be successfully used for the treatment of patients with FIGO IIIC ETOC or PPSC, offering 30 and 25 months of median PFS in the paclitaxel-cisplatin and paclitaxel-carboplatin groups, respectively. The median OS was 58.5 months in the paclitaxel-cisplatin group and 55.0 months in the paclitaxel-carboplatin group. Although neither PFS nor OS reached the statistically significant difference, it seemed to be little better in patients treated with the paclitaxel-cisplatin regimen compared to those treated with the paclitaxel-carboplatin regimen. However, to compare the frequency and severity of AEs, we found that patients in the paclitaxel-carboplatin group had more AEs than those in paclitaxel-cisplatin group did, including a higher risk of neutropenia and grade 3/4 neutropenia, and the need for a longer period to complete the front-line chemotherapy. The need for a longer period to finish the dose-dense therapy seemed to be associated with a worse outcome for patients. Further analysis showed that the period between the first-time chemotherapy to the last dose (6 cycles) of chemotherapy &gt; 21 weeks was associated with worse prognosis in patients compared to that ≤21 weeks, with hazard ratio (HR) of 81.24 for PFS and 9.57 for OS. As predicted, suboptimal debulking surgery (&gt;1 cm) also contributed to the worse outcome than optimal debulking surgery (≤1 cm) with a HR of 14.38 for PFS and 11.83 for OS <ref type="table" target="#tab_3">(Tables 3 and 4</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.">Summary of Studies</head><p>Addressing Dose-Dense therapy: Survival Outcome <ref type="table" target="#tab_8">(Table 5)</ref> Some early phase studies have also been conducted to test the tolerability and efficacy of dose-dense weekly paclitaxel (80 mg/m 2 ) and triweekly carboplatin (AUC 5) with other agents <ref type="bibr" target="#b133">[132,</ref><ref type="bibr" target="#b134">133]</ref>. For example, one phase II study modified a dose-dense paclitaxel (80 mg/m 2 ) and carboplatin (AUC 5) every four weeks for the treatment of advanced-stage ETOC patients, and found that the median PFS and OS were 22.5 and 31.5 months, respectively <ref type="bibr" target="#b133">[132]</ref>. Another phase II study adding bevacizumab in dose-dense chemotherapy (weekly paclitaxel 80 mg/m 2 and triweekly carboplatin AUC 5) showed that the median PFS was 16.9-22.4 months in advanced-stage ETOC patients <ref type="bibr" target="#b134">[133]</ref>.</p><p>Based on the impressive survival benefits of the earlier reports, the prospective, randomized trials may be the best method to test the efficacy and safety of dose-dense chemotherapy in the management of ETOC patients. The first large study, named as the JGOG 3016 has shown the survival benefits in dose-dense regimen containing weekly paclitaxel (80 mg/m 2 ) and triweekly carboplatin (AUC 6), which not only offered a longer PFS (median PFS of 28.2 months, 95% CI 22.3-33.8 months) but also a significantly prolonged OS (median OS of 100.5 months, 95% CI 65.2-∞ months) than those in the standard triweekly paclitaxel-carboplatin regimen <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref>.</p><p>The results of an NRG Oncology/GOG Study showed a similar PFS (the median PFS of 24.9 months) and OS (the median OS of 75.5 months) in dose-dense weekly paclitaxel (80 mg/m 2 ) and triweekly carboplatin (AUC 6) with 15 mg/kg bevacizumab treatment compared to the standard triweekly combination therapy <ref type="bibr" target="#b71">[72]</ref>.</p><p>MITO-7 has shown that there was no statistically significant difference in median PFS between dose-dense weekly combination (paclitaxel 60 mg/m 2 plus carboplatin AUC 2) and standard triweekly combination therapy <ref type="bibr">(18.3</ref>   <ref type="bibr" target="#b31">[32]</ref>.</p><p>GOG-0262 showed the median PFS of 14.9 and 14.2 months in dose-dense weekly paclitaxel (80 mg/m 2 ) and triweekly carboplatin (AUC 6) with/without adding 15 mg/kg bevacizumab treatment, respectively, without a statistically significant difference compared to the standard triweekly combination therapy <ref type="bibr" target="#b40">[41]</ref>.</p><p>The results from an ICON8 have shown that the median PFS was 20.8 months (95% CI 11.9-59.0 months) and 21.0 months (95% CI 12.0-54.0 months) in dose-dense weekly paclitaxel (80 mg/m 2 ) and triweekly carboplatin (AUC 5 or 6) and in dose-dense weekly paclitaxel (80 mg/m 2 ) and weekly carboplatin (AUC 2) regimen, respectively, and none were statistically significant different from the 17.7-month median PFS in the standard-dose triweekly paclitaxel and triweekly carboplatin (AUC) treatment <ref type="bibr" target="#b32">[33]</ref>.</p><p>Although the evidence would be much more powerful if the results were obtained from prospective, randomized trials, the management of the individual patient who does not fulfill the criteria of a clinical trial or is enrolled into the clinical trial will be debated continuously. In addition, the strict criteria of a clinical trial, such as inclusive and exclusive criteria, may not reflect the real situations of patients. Therefore, clinical practices are not uniform, and retrospective evaluations may partly reveal real-world clinical practice. For example, the elderly population is often excluded in clinical trials. Dr. Bun and colleagues found dose-dense weekly paclitaxel plus triweekly carboplatin was feasible for elderly patients, although severe neuropathy might occur more frequently than in younger groups <ref type="bibr" target="#b135">[134]</ref>. In fact, the elderly population might have a higher risk of receiving nonstandard chemotherapy <ref type="bibr" target="#b136">[135]</ref>. <ref type="table" target="#tab_8">Table 5</ref>. Summary of treatment efficacy and safety of dose-dense weekly paclitaxel plus platinum compounds in the management of patients with epithelial tubo-ovarian cancer and primary peritoneal serous carcinoma.   It is believed that the use of carboplatin in place of original cisplatin in the platinum compound-based paclitaxel doublet might provide a better quality of life (QOL) in the long-term, since this regimen-with carboplatin dosed using the Calvert formula-yielded convincing non inferior outcomes when compared with the prior, more toxic, cisplatin-paclitaxel regimen <ref type="bibr" target="#b137">[136]</ref>. By contrast, bone marrow suppression, including the toxicity of hematological system might be more apparent in carboplatin administration, although Boyd and Muggia proposed that carboplatin-paclitaxel therapy is generally safe when the drug is properly dosed <ref type="bibr" target="#b137">[136]</ref>. The occurrence of neutropenia is one of the most common causes necessitating postponing the therapy or modifying (decreasing) the dosage of therapeutic agent. One study from Japan in 2006 tried to determine the feasibility of docetaxel-cisplatin therapy Q3W compared with docetaxel-carboplatin therapy Q3W as a front-line for ETOC patients <ref type="bibr" target="#b137">[136]</ref>. The results, as predicted, showed that the incidence of grade 4 neutropenia was much higher in the docetaxel-carboplatin group than that in the docetaxel-cisplatin group (74% versus 39%), suggesting the feasibility of docetaxel-cisplatin combination therapy as front-line therapy for ETOC patients <ref type="bibr" target="#b137">[136]</ref>. In addition, the rationale of the use of "dose-dense" in place of "standard-dose" is the attempt to decrease the incidence of chemotherapy-related severe hematotoxicity, such as infection or sepsis caused by severe neutropenia or spontaneous hemorrhage caused by severe thrombocytopenia <ref type="bibr" target="#b48">[49]</ref>. In Taiwan, GCSF is not routinely prescribed and insurance does not cover the cost if GCSF is used in a prophylactic role. Furthermore, the obstacle is still present when facing patients with chemotherapy-related thrombocytopenia <ref type="bibr" target="#b138">[137]</ref><ref type="bibr" target="#b139">[138]</ref><ref type="bibr" target="#b140">[139]</ref>.</p><p>Thrombocytopenia is a principal consideration, as well as the dose-limiting toxicity of carboplatin <ref type="bibr" target="#b141">[140,</ref><ref type="bibr" target="#b142">141]</ref>. Although thrombocytopenia unlikely occurs in chemotherapy-naïve patients, this toxicity usually begins to appear after day 14 and is predictably cumulative, contributing to the consideration of a carboplatin dose reduction <ref type="bibr" target="#b141">[140]</ref>. Due to aforementioned limitation, some gynecological oncologists favored the use of cisplatin as the drug in the platinum-based combination therapy, except for those patients with identified impaired renal function (eGFR &lt; 60 ml/min). The current low-dose cisplatin plus dose-dense paclitaxel regimen was associated with lower rates of hematologic toxicities compared to the conventional dose-dense paclitaxel plus carboplatin regimen. The results from an ICON8 have also shown that patients treated with a weekly regimen had increased grade 3 or 4 toxic effects, although these high-grade toxicities were predominantly uncomplicated <ref type="bibr" target="#b32">[33]</ref>. However, both regimens are carboplatin-based paclitaxel combinations.</p><p>Consistent with the increased toxicity of the use of carboplatin in previous studies <ref type="bibr" target="#b137">[136]</ref>, the incidence of grade 3/4 neutropenia was significantly lower in the cisplatin-paclitaxel arm than in that of the carboplatin-paclitaxel arm (27.8% versus 77.3%, p = 0.002) in our study. In addition, other parameters of hematological examination, including grade 3/4 anemia and grade 3/4 thrombocytopenia also favored the cisplatin-paclitaxel regimen with incidence of 5.6% and none, respectively, compared to 22.7% and 13.6% in the carboplatin-paclitaxel regimen in the current study. We believe that this carboplatin-paclitaxel combination therapy-related hematotoxicity might explain why more patients in the carboplatin-paclitaxel arm had a prolongation of the period between the initial first dose of chemotherapy and the final dose of chemotherapy (six cycles of chemotherapy) than those in the cisplatin-paclitaxel arm (45% versus 11.1%, p = 0.018). Further survival analysis showed that this prolongation of the therapeutic period might be associated with a worse outcome in FIGO IIIC ETOC and PPSC patients.</p><p>By contrast, the cisplatin-related renal, neural, and gastrointestinal system toxicity was lower in the current study. The main reason is the use of low-dose cisplatin (20 mg/m 2 ) as a platinum compound in the platinum-paclitaxel combination therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.">The Benefits of Maximal Cytoreductive Surgery and The Consideration of the Location of Residual Tumors</head><p>In agreement with well-known concepts <ref type="bibr" target="#b143">[142]</ref><ref type="bibr" target="#b144">[143]</ref><ref type="bibr" target="#b145">[144]</ref><ref type="bibr" target="#b146">[145]</ref><ref type="bibr" target="#b147">[146]</ref>, a rapid reduction in the tumor burden is the guarantee of successful treatment in cancer patients. Nearly all studies have confirmed that maximal cytoreduction surgery is the most critical step in the management of patients with advanced-stage ETOC or PPSC <ref type="bibr" target="#b143">[142]</ref><ref type="bibr" target="#b144">[143]</ref><ref type="bibr" target="#b145">[144]</ref><ref type="bibr" target="#b146">[145]</ref><ref type="bibr" target="#b147">[146]</ref>. According to the definition of the Gynecologic Oncology group (GOG) for 'optimal' as having residual tumor nodules which should be ≤ 1 cm in size, the Cochrane review revealed that the outcome of ETOC patients with residual disease ≤ 1 cm is better than of those with residual disease &gt; 1 cm <ref type="bibr" target="#b144">[143]</ref>, although it is well known that PCS to no gross residual tumor might be associated with the longest PFS and OS <ref type="bibr" target="#b145">[144,</ref><ref type="bibr" target="#b146">145]</ref>. One study showed an interesting finding that patients still had diverse outcomes despite undergoing optimal PCS (≤ 1 cm residual disease), in which it demonstrated that patients with a tumor limited in a single anatomic location had better median PFS and OS than patients with tumors widely distributed in multiple anatomic locations <ref type="bibr" target="#b147">[146]</ref>.</p><p>In our current study, we also tested the aforementioned findings. We found that patients with suboptimal PCS with a residual tumor &gt; 1 cm indeed had a worse prognosis, with a hazard ratio (HR) of 14.38 (95% confidence interval [CI] 4.18-49.46) in PFS and a HR of 11.83 (95% CI 1.48-94.72) in OS, compared with those patients who could achieve optimal PCS with a residual tumor of a size less than 1 cm, supporting the rationale that small-volume tumors are more prone to clearance <ref type="bibr" target="#b60">[61]</ref>. However, the widespread nature of tumors seemed to not be an independent risk factor for worse prognosis. We found that there was no statistically significant difference of outcome in patients whose residual tumors were in localized anatomical site or in multiple anatomical sites.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.">The Strengths and Limitations</head><p>The current study has the following strengths: All patients were serous-type ETOC and PPSC with FIGO stage IIIC. The follow-up period was long enough, of nearly 5 years (a mean follow-up period of 55 months). All patients were treated with by one senior doctor (P.-H.W). All the suggested study population was homogeneous.</p><p>There are some limitations in the current study. Retrospective data collection in nature may not be strong enough to show clear evidence. However, as shown above, this is a real-world clinical practice. In addition, only patients who underwent PCS with surgical confirmation of FIGO IIIC serous-type ETOC and PPSC and completed 6 cycles of dose-dense paclitaxel-platinum compounds were included, contributing to the risk of selection bias. Furthermore, the number of patients in the current study was small in each arm, contributing to wide confidence intervals. It demonstrated the higher risk of low precision in the estimates. Therefore, the findings of the current study should be used with caution. Finally, new therapeutic strategies-such as maintenance therapy, NACT, or intraperitoneal therapy-were not evaluated in the current report. However, we believe none of them impede the value of the current study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions</head><p>Our study found that paclitaxel might be one of the most critical components for the successful administration of dose-dense adjuvant chemotherapy. In addition, the on-schedule delivery and shortening of the entire therapeutic period are a critical step for the survival benefits of patients who undergo a postoperative adjuvant dose-dense paclitaxel plus platinum compounds regimen. Of course, maximal efforts should be made to eradicate the tumor as much as possible. Although recent evidences highlighted the value of precise medicine, personalized and individual therapy, along with targeted therapy for cancer patients <ref type="bibr" target="#b148">[147]</ref><ref type="bibr" target="#b149">[148]</ref><ref type="bibr" target="#b150">[149]</ref><ref type="bibr" target="#b151">[150]</ref><ref type="bibr" target="#b152">[151]</ref>-the net health benefits (NHBs), cost-effectiveness or quality of life may reflect the relative value of treatment options in EOC <ref type="bibr" target="#b100">[100,</ref><ref type="bibr" target="#b153">[152]</ref><ref type="bibr" target="#b154">[153]</ref><ref type="bibr" target="#b155">[154]</ref><ref type="bibr" target="#b156">[155]</ref><ref type="bibr" target="#b157">[156]</ref><ref type="bibr" target="#b158">[157]</ref>. With the low risk of AEs, shortened therapeutic period, and, of most importance, working without compromising therapeutic effects-low-dose triweekly cisplatin plus dose-dense weekly paclitaxel might be associated with better NHBs, a better cost-effectiveness, and a better QOL compared to a carboplatin-based dose-dense paclitaxel regimen. More studies are encouraged to test our findings.</p><p>Poly(ADP-ribose) polymerase (PARP) inhibitors (PARP inhibitors) Primary peritoneal serous carcinoma (PPSC) Primary cytoreductive surgery (PSC) Primary debulking surgery (PDS) Progression-free survival (PFS) Progressive disease (PD) Quality of life (QOL) Response Evaluation Criteria in Solid Tumors (RECIST)</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Progression-free survival curves for patients treated either with carboplatin-based dose-dense chemotherapy or with cisplatin-based dose-dense chemotherapy.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc>Progression-free survival curves for patients treated either with carboplatin-based dose-dense chemotherapy or with cisplatin-based dose-dense chemotherapy.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc>Overall survival curves of patients for patients treated either with carboplatin-based dose-dense chemotherapy or with cisplatin-based dose-dense chemotherapy.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2 .</head><label>2</label><figDesc>Overall survival curves of patients for patients treated either with carboplatin-based dose-dense chemotherapy or with cisplatin-based dose-dense chemotherapy.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc>chemotherapy is limited on the intravenous route. RCT: randomized control trial, containing co-administration of bevacizumab (BEV) 15 mg/kilograms at day 1 triweekly and patients treated with neoadjuvant chemotherapy; n: number of patients; PFS: median (M) or mean (m) progression-free survival calculated by months; OS: median or mean overall survival calculated by months; Stage: FIGO stage (International Federation of Gynecology and Obstetrics stage); P: paclitaxel; D: day; C 2, C 5 or C 6: carboplatin (AUC 2, AUC 5 or AUC 6: area under the curve 2, 5, or 6 mg/mL per minute). 4.3. Dose-Dense Therapy-Related Adverse Events: Prefer the Use of Low-Dose Cisplatin in Place of Carboplatin in Platinum-based Therapy</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>Characteristics of the patients with FIGO IIIC serous type epithelial tubo-ovarian cancer, or primary peritoneal carcinoma treated with weekly paclitaxel (80 mg/m 2 ) plus either carboplatin (AUC 5) or cisplatin (20 mg/m 2 ) combination chemotherapy triweekly.</figDesc><table><row><cell>Carboplatin</cell><cell>Cisplatin</cell><cell>p</cell></row></table><note>Carboplatin: carboplatin (AUC 5)-based dose dense chemotherapy; Cisplatin: cisplatin (20mg/m 2 )-based dose dense chemotherapy; ECOG: Eastern Cooperative Oncology Group Performance Status. Data are presented as a number (%) or the mean ± standard deviation.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc>Association between baseline characteristics and progression-free survival.</figDesc><table><row><cell>Parameters</cell><cell></cell><cell cols="2">Univariate Analysis</cell><cell cols="2">Multivariate Analysis</cell></row><row><cell></cell><cell>n</cell><cell>HR (95% CI)</cell><cell>p</cell><cell>HR (95% CI)</cell><cell>p</cell></row><row><cell>Size</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≤1cm</cell><cell>22</cell><cell>1(Ref)</cell><cell></cell><cell>1(Ref)</cell><cell></cell></row><row><cell>&gt;1cm</cell><cell>18</cell><cell>8.68 (3.23-23.35)</cell><cell>&lt;0.0001</cell><cell>14.38 (4.18-49.46)</cell><cell>&lt;0.0001</cell></row><row><cell>Site</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Localized</cell><cell>23</cell><cell>1 (Ref)</cell><cell></cell><cell>1 (Ref)</cell><cell></cell></row><row><cell>WAC</cell><cell>17</cell><cell>1.38 (0.61-3.14)</cell><cell>0.440</cell><cell>0.71 (0.28-1.82)</cell><cell>0.470</cell></row><row><cell>Period</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≤21 weeks</cell><cell>28</cell><cell>1 (Ref)</cell><cell></cell><cell>1 (Ref)</cell><cell></cell></row><row><cell>&gt;21 weeks</cell><cell>12</cell><cell>28.49 (8.36-97.06)</cell><cell>&lt;0.0001</cell><cell>81.24 (14.03-470.31)</cell><cell>&lt;0.0001</cell></row><row><cell cols="6">n: number of patients; HR: hazard ratio; 95% CI: 95% confidence interval; Size: size of residual tumor;</cell></row></table><note>Site: site of residual tumor; Localized: a single anatomic site; WAC whole abdominal cavity similar to multiple anatomic sites; Period: period between the initial first time of chemotherapy and the end of final chemotherapy (six cycles of chemotherapy); Ref: reference.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4 .</head><label>4</label><figDesc>Association between baseline characteristics and overall survival.</figDesc><table><row><cell>Parameters</cell><cell></cell><cell cols="2">Univariate Analysis</cell><cell cols="2">Multivariate Analysis</cell></row><row><cell></cell><cell>n</cell><cell>HR (95% CI)</cell><cell>p</cell><cell>HR (95% CI)</cell><cell>p</cell></row><row><cell>Size</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≤1cm</cell><cell>22</cell><cell>1(Ref)</cell><cell></cell><cell>1(Ref)</cell><cell></cell></row><row><cell>&gt;1cm</cell><cell>18</cell><cell>22.37 (2.88-173.86)</cell><cell>0.003</cell><cell>11.83 (1.48-94.72)</cell><cell>0.020</cell></row><row><cell>Site</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Localized</cell><cell>23</cell><cell>1 (Ref)</cell><cell></cell><cell>1 (Ref)</cell><cell></cell></row><row><cell>WAC</cell><cell>17</cell><cell>2.41 (0.79-7.39)</cell><cell>0.122</cell><cell>2.54 (0.76-8.53)</cell><cell>0.131</cell></row><row><cell>Period</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≤21 weeks</cell><cell>28</cell><cell>1 (Ref)</cell><cell></cell><cell>1 (Ref)</cell><cell></cell></row><row><cell>&gt;21 weeks</cell><cell>12</cell><cell>15.31 (4.13-56.78)</cell><cell>&lt;0.0001</cell><cell>9.57 (2.34-39.18)</cell><cell>0.002</cell></row><row><cell cols="6">n: number of patients; HR: hazard ratio; 95% CI: 95% confidence interval; Size: size of residual tumor; Site: site</cell></row><row><cell cols="6">of residual tumor; Localized: a single anatomic site; WAC whole abdominal cavity similar to multiple anatomic</cell></row><row><cell cols="6">sites; Period: period between the initial first time of chemotherapy and the end of final chemotherapy (six cycles of</cell></row><row><cell cols="2">chemotherapy); Ref: reference.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head></head><label></label><figDesc>months [95% CI 16.8-20.9 months] versus 17.3 months [95% CI 15.2-20.2 months]) with a HR of 0.96, 95% CI 0.80-1.16</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 5 .</head><label>5</label><figDesc>Cont.</figDesc><table><row><cell>Authors</cell><cell>Stage</cell><cell>n</cell><cell>Regimen</cell><cell>PFS</cell><cell>OS</cell></row><row><cell>Boraska Jelavić [105]</cell><cell>I-IV</cell><cell>43</cell><cell>P 80 mg/m 2 (D1,8,15), C 5 (D1)</cell><cell>20-24 (M)</cell><cell></cell></row><row><cell>Rettenmaier [78]</cell><cell>I-IV</cell><cell>100</cell><cell>P 80 mg/m 2 (D1,8,15), C 5 (D1)</cell><cell>27.6 (M)</cell><cell></cell></row><row><cell>Cheng [101]</cell><cell>IIIC-IV</cell><cell>32</cell><cell>P 80 mg/m 2 (D1,8,15), Cisplatin 20 mg/m 2 (D1)</cell><cell>27.0 (M)</cell><cell>56 (m)</cell></row><row><cell>Current study</cell><cell>IIIC</cell><cell>18</cell><cell>P 80 mg/m 2 (D1,8,15), Cisplatin 20 mg/m 2 (D1)</cell><cell>30.0 (M)</cell><cell>58.5 (M)</cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Int. J. Environ. Res. Public Health 2020,<ref type="bibr" target="#b16">17,</ref> 2213  </note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer of the ovary, fallopian tube, and peritoneum</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Berek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">T</forename><surname>Kehoe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijgo.12614</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Gynaecol. Obstet</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="59" to="78" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>Suppl. 2. PubMed</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Torre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Trabert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">E</forename><surname>Desantis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">D</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Samimi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">D</forename><surname>Runowicz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Gaudet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Siegel</surname></persName>
		</author>
		<idno type="DOI">10.3322/caac.21456</idno>
	</analytic>
	<monogr>
		<title level="j">Ovarian cancer statistics</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="284" to="296" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>CA Cancer J. Clin. PubMed</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Survival disparities among racial/ethnic groups of women with ovarian cancer: An update on data from the Surveillance, Epidemiology and End Results (SEER) registry</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">E</forename><surname>Stenzel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Buas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">B</forename><surname>Moysich</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.canep.2019.101580</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer. Epidemiol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">NCCN guidelines insights: Ovarian cancer, version 1</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">K</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">N</forename><surname>Bakkum-Gamez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Barroilhet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Behbakht</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Berchuck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Berek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Cristea</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Derosa</surname></persName>
		</author>
		<idno type="DOI">10.6004/jnccn.2019.0039</idno>
	</analytic>
	<monogr>
		<title level="j">J. Natl. Compr. Cancer Netw</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="896" to="909" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Ovarian cancer incidence in the U.S. and toxic emissions from pulp and paper plants: A geospatial analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Hanchette</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">G</forename><surname>Schwartz</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph15081619</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">1619</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">N</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">T</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">U</forename><surname>Chern</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">W</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">H</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Tsui</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph16091510</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">1510</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Risk of endometriosis and subsequent ovary and breast cancers in nurses: A population-based cohort study in Taiwan</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">Y</forename><surname>Tseng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">C</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">F</forename><surname>Ma</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph16183469</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">3469</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Oda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Hamanishi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Matsuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hasegawa</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2018.09.001</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="381" to="389" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Murakami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Kotani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Shiro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Takaya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Nakai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Matsumura</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10147-019-01536-5</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="51" to="58" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Development of ovarian cancer after excision of endometrioma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Haraguchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Koga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Takamura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Makabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Sue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Miyashita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Urata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Izumi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Hirata</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.fertnstert.2016.07.1077</idno>
	</analytic>
	<monogr>
		<title level="j">Fertil. Steril</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1432" to="1437" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The recent progress and therapy in endometriosis-associated ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<idno type="DOI">10.1097/JCMA.0000000000000262</idno>
	</analytic>
	<monogr>
		<title level="j">J. Chin. Med. Assoc</title>
		<imprint>
			<biblScope unit="volume">2020</biblScope>
			<biblScope unit="page" from="227" to="232" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Cell origins of high-grade serous ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Schilder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Coffey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">C</forename><surname>Bast</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Jr</surname></persName>
		</author>
		<idno type="DOI">10.3390/cancers10110433</idno>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">433</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Lisio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Goyeneche</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">H</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Telleria</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms20040952</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The association and significance of p53 in gynecologic cancers: The potential of targeted therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Obata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Daikoku</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Fujiwara</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms20215482</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Jiang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tjog.2019.07.008</idno>
	</analytic>
	<monogr>
		<title level="j">Taiwan J. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="626" to="632" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Exploring the role of Fallopian ciliated cells in the pathogenesis of high-grade serous ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Coan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">L</forename><surname>Rampioni Vinciguerra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Cesaratto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Gardenal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Bianchet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Dassi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Vecchione</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Baldassarre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Spizzo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Nicoloso</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms19092512</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Key immunological functions involved in the progression of epithelial ovarian serous carcinoma discovered by the gene ontology-based immunofunctionome analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">K</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">K</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Chang</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms19113311</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">3311</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">L</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">C</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">F</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Tseng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">T</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">C</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">H</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Chuang</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0185615</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">P</forename><surname>Mcguire</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Hoskins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Kucera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">E</forename><surname>Partridge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">Y</forename><surname>Look</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Clarke-Pearson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Davidson</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM199601043340101</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">334</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="1996" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Piccart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Bertelsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Cassidy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Mangioni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Simonsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Blom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Gynecol. Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="144" to="148" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Piccart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Bertelsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Cassidy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Mangioni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Simonsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Blom</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/92.9.699</idno>
	</analytic>
	<monogr>
		<title level="j">J. Natl. Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="699" to="708" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Carboplatin versus cisplatin in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Alberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin. Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="88" to="90" />
			<date type="published" when="1995" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Neijt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Engelholm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">K</forename><surname>Tuxen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">G</forename><surname>Sorensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Sessa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>De Swart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">R</forename><surname>Hirsch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Lund</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Van Houwelingen</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2000.18.17.3084</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="3084" to="3092" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Lück</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">P</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Mobus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Bauknecht</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Warm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Schröder</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djg036</idno>
	</analytic>
	<monogr>
		<title level="j">J. Natl. Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1320" to="1329" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">F</forename><surname>Ozols</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">N</forename><surname>Bundy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">E</forename><surname>Greer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Clarke-Pearson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Mannel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Degeest</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">M</forename><surname>Hartenbach</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Baerge</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2003.02.153</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3194" to="3200" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer</title>
		<ptr target="https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf." />
		<imprint>
			<date type="published" when="2020-03-11" />
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">18</biblScope>
		</imprint>
		<respStmt>
			<orgName>NCCN Clinical Practice Guideline in Oncology</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">S</forename><surname>Tewari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Enserro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">M</forename><surname>Norquist</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">M</forename><surname>Swisher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Bookman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">F</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">D</forename><surname>Homesley</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.19.01009</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2317" to="2328" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">Anti-angiogenesis therapy in ovarian cancer: Which patient is it most likely to benefit? Oncology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Chelariu-Raicu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">K</forename><surname>Sood</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2019" />
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">629378</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Oza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">D</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Embleton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Ledermann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Pujade-Lauraine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kristensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Beale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Cervantes</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(15)00086-8</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="928" to="936" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">A phase 3 trial of bevacizumab in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Perren</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Swart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Ledermann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Pujade-Lauraine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kristensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Beale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Cervantes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Kurzeder</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1103799</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="2484" to="2496" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>et al. ICON7 Investigators</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Bookman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">F</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">J</forename><surname>Monk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Mannel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">D</forename><surname>Homesley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">E</forename><surname>Greer</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1104390</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="2473" to="2483" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pignata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Scambia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Katsaros</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Gallo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Pujade-Lauraine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>De Placido</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bologna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Raspagliesi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">B</forename><surname>Panici</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(14)70049-X</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="396" to="405" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): Primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">R</forename><surname>Clamp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">C</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">A</forename><surname>Mcneish</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Dean</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Donnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Hook</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Coyle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Blagden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Brenton</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(19)32259-7</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">394</biblScope>
			<biblScope unit="page" from="2084" to="2095" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Vasey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">C</forename><surname>Jayson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Gabra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Atkinson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Parkin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">B</forename><surname>Kaye</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djh323</idno>
	</analytic>
	<monogr>
		<title level="j">J. Natl. Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="1682" to="1691" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hosokawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Kinoshita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Kuroboshi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Yasuda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Fujita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Nakata</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10147-007-0656-z</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="205" to="211" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pignata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Scambia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Ferrandina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Savarese</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Sorio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Breda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Gebbia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Musso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Frigerio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Del Medico</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2010.33.8566</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="3628" to="3635" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Bookman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">P</forename><surname>Mcguire</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">G</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Alberts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Argenta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>De Geest</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2008.19.1684</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1419" to="1425" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Staropoli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Ciliberto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Botta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Fiorillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Grimaldi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Caraglia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Salvino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Tassone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Tagliaferri</surname></persName>
		</author>
		<idno type="DOI">10.4161/cbt.28557</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer. Biol. Ther</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="707" to="720" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Katsumata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Yasuda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Isonishi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Jobo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Aoki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Tsuda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Sugiyama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kodama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kimura</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(09)61157-0</idno>
	</analytic>
	<monogr>
		<title level="j">Japanese Gynecologic Oncology Group</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="1331" to="1338" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note>Lancet</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Katsumata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Yasuda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Isonishi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Michimae</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kimura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Aoki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Jobo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kodama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Terauchi</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(13)70363-2</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1020" to="1026" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">K</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">T</forename><surname>Penson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Birrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Disilvestro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">C</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">P</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Davidson</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1505067</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="738" to="748" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fujiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hasegawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Nagao</surname></persName>
		</author>
		<idno type="DOI">10.1002/cncr.32475</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">2019</biblScope>
			<biblScope unit="page" from="4582" to="4586" />
		</imprint>
	</monogr>
	<note>Suppl. 24. PubMed</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">K</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Bundy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Wenzel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Baergen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lele</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Copeland</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Burger</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa052985</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page" from="34" to="43" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Markman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">N</forename><surname>Bundy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Alberts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Clark-Pearson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">F</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Wadler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Sickel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1001" to="1007" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Ovarian cancer: Current status and strategies for improving therapeutic outcomes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Chandra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Pius</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nabeel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nair</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">K</forename><surname>Vishwanatha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ahmad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Basha</surname></persName>
		</author>
		<idno type="DOI">10.1002/cam4.2560</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="7018" to="7031" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lheureux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Gourley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Oza</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(18)32552-2</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">393</biblScope>
			<biblScope unit="page" from="1240" to="1253" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Marchetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>De Felice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Di Pinto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>D'oria</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Aleksa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Musella</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.critrevonc.2018.02.016</idno>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Oncol. Hematol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="30" to="34" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Front-line therapy of advanced epithelial ovarian cancer: Standard treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Marth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Reimer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">G</forename><surname>Zeimet</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mdx450</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="36" to="39" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Update on first-line treatment of advanced ovarian carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Kemp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ledermann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Womens Health</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="45" to="51" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">First-line chemotherapy in epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Bookman</surname></persName>
		</author>
		<idno type="DOI">10.1097/GRF.0b013e31824b45da</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="96" to="113" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Paclitaxel-related dermatological problems: Not only alopecia occurs</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">C</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tjog.2019.08.003</idno>
	</analytic>
	<monogr>
		<title level="j">Taiwan. J. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="877" to="879" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">A case of ovarian cancer present with acute respiratory distress: Spontaneous rupture of diaphragm</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Horng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tjog.2019.07.024</idno>
	</analytic>
	<monogr>
		<title level="j">Taiwan J. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="712" to="714" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Update on the differential diagnosis of gynecologic organ-related diseases in women presenting with ascites</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">S</forename><surname>Kung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tjog.2019.07.002</idno>
	</analytic>
	<monogr>
		<title level="j">Taiwan J. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="587" to="591" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Prognostic factors of early stage epithelial ovarian carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">F</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Y</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">H</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">F</forename><surname>Twu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">F</forename><surname>Cheng</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph16040637</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Effect of chemotherapy, laparoscopy, and cytology on stage IC ovarian clear cell carcinoma: A long-term, single-center study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">T</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Chiu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">H</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph17020491</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">491</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">New strategies in ovarian cancer treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Minasian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">C</forename><surname>Kohn</surname></persName>
		</author>
		<idno type="DOI">10.1002/cncr.32544</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">2019</biblScope>
			<biblScope unit="page" from="4623" to="4629" />
		</imprint>
	</monogr>
	<note>Suppl. 24</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Hopes and failures in front-line ovarian cancer therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Tsibulak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">G</forename><surname>Zeimet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Marth</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.critrevonc.2019.08.002</idno>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Oncol. Hematol</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="14" to="19" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Phase III trials in ovarian cancer: The evolving landscape of front line therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Wendel Naumann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">N</forename><surname>Moore</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2019.02.008</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="436" to="444" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">New advances in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><forename type="middle">A</forename><surname>Matulonis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncology</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="721" to="728" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Limited use of the intraperitoneal route for ovarian cancer-why?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Markman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Chemotherapy</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrclinonc.2015.177</idno>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="628" to="630" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Van Der Burg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Van Lent</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Buyse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Kobierska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Favalli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Lacave</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nardi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Renard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pecorelli</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM199503093321002</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">332</biblScope>
			<biblScope unit="page" from="629" to="634" />
			<date type="published" when="1995" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">G</forename><surname>Trope</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Amant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">B</forename><surname>Kristensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ehlen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Verheijen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Van Der Burg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Lacave</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">B</forename><surname>Panici</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0908806</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="943" to="953" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">G</forename><surname>Tropé</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Amant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ehlen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">S</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Casado</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2011.36.9785</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="4076" to="4078" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kusunoki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Terao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Hirayama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fujino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ujihira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ota</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Takeda</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tjog.2018.08.006</idno>
	</analytic>
	<monogr>
		<title level="j">Taiwan J. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="650" to="653" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tjog.2018.08.001</idno>
	</analytic>
	<monogr>
		<title level="j">Taiwan J. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="623" to="624" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Bartels</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">C</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Mcsharry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Mcvey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">D</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Brennan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2019.07.011</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="622" to="630" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: A retrospective study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Shibutani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Nagao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kaneda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Jimi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Yano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kitai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Shiozaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Matsuoka</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10147-019-01567-y</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Clin. Oncol</title>
		<imprint>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">N</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">J</forename><surname>Nam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">T</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.3802/jgo.2020.31.e23</idno>
	</analytic>
	<monogr>
		<title level="j">J. Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">2020</biblScope>
		</imprint>
	</monogr>
	<note>e23. [CrossRef</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Coleridge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bryant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Lyons</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Goodall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kehoe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Morrison</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.CD005343.pub4</idno>
	</analytic>
	<monogr>
		<title level="j">Cochrane. Database. Syst. Rev</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hasegawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Shimada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Takeuchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Fujiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Imai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Iwasa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Wada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Eguchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Oishi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Sugiyama</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41416-020-0734-9</idno>
	</analytic>
	<monogr>
		<title level="j">Br. J. Cancer</title>
		<imprint>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: A randomised controlled study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Pu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Jia</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41416-019-0543-1</idno>
	</analytic>
	<monogr>
		<title level="j">Br. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="425" to="428" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Wenzel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">F</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Disilvestro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fujiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Alberts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">S</forename><surname>Tewari</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.18.01568</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1380" to="1390" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Role of intraperitoneal chemotherapy in ovarian cancer in the platimum-taxane-based era: A meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Marchetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>De Felice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Perniola</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Palaia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Musella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Di Donato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Cascialli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Cascialli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Muzii</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Tombolini</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.critrevonc.2019.01.002</idno>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Oncol. Hematol</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="64" to="69" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Hyperthermic intraperitoneal chemotherapy in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Van Driel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">N</forename><surname>Koole</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Sikorska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Schagen Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">W R</forename><surname>Schreuder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H M</forename><surname>Hermans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H M</forename><surname>Hermans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">H J T</forename><surname>De Hingh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Van Der Velden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Arts</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1708618</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="230" to="240" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: A systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">C</forename><surname>Auer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Sivajohanathan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Biagi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Conner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kennedy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>May</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejca.2019.10.034</idno>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">2020</biblScope>
			<biblScope unit="page" from="76" to="95" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Incorporation of pazopanib in maintenance therapy of ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Floquet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Rau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Del Campo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pignata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fujiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2014.55.7348</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="3374" to="3382" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kristensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Ray-Coquard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Reuss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pignata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Denison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Del Campo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Ottevanger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">A randomised, double-blind</title>
		<imprint>
			<date type="published" when="2016" />
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="78" to="89" />
		</imprint>
	</monogr>
	<note>AGO-OVAR</note>
</biblStruct>

<biblStruct xml:id="b77">
	<monogr>
		<title level="m" type="main">Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Oza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Lorusso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Aghajanian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Oaknin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Dean</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">I</forename><surname>Weberpals</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Clamp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Scambia</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(17)32440-6</idno>
		<imprint>
			<date type="published" when="2017" />
			<biblScope unit="volume">390</biblScope>
			<biblScope unit="page" from="1949" to="1961" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Poly</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tjog.2017.08.026</idno>
	</analytic>
	<monogr>
		<title level="j">Taiwan J. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="713" to="714" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Scambia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">G</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Oaknin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lisyanskaya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Floquet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Leary</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Sonke</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1810858</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page" from="2495" to="2505" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Floquet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Rau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Del Campo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pignata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fujiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2019.08.024</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="186" to="191" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: A literature review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Boussios</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Karihtala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Moschetta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Karathanasi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Sadauskaite</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Rassy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Pavlidis</surname></persName>
		</author>
		<idno type="DOI">10.3390/diagnostics9030087</idno>
	</analytic>
	<monogr>
		<title level="j">Diagnostics</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Comparison of PARPis with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: A network meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12325-019-01106-1</idno>
	</analytic>
	<monogr>
		<title level="j">Adv. Ther</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="3368" to="3380" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): A randomised, double-blind</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Scambia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>O'malley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Van Calster</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Del Campo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bamias</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Wenham</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(19)30178-0</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="862" to="876" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">F</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">M</forename><surname>Swisher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">D</forename><surname>Steffensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">N</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Ben-Baruch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">L</forename><surname>Werner</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1909707</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">381</biblScope>
			<biblScope unit="page" from="2403" to="2415" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Advancing drug development in gynecologic malignancies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Beaver</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">C</forename><surname>Arend</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">K</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Bala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">B</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">K</forename><surname>Sood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Herzog</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-19-0619</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="4874" to="4880" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Aberrant sialylation in ovarian cancers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1097/JCMA.0000000000000252</idno>
	</analytic>
	<monogr>
		<title level="j">J. Chin. Med. Assoc</title>
		<imprint>
			<biblScope unit="volume">2020</biblScope>
			<biblScope unit="page" from="337" to="344" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Matanes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Gotlieb</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bpobgyn.2019.03.005</idno>
	</analytic>
	<monogr>
		<title level="j">Immunotherapy of gynecological cancers. Best Pract. Res. Clin. Obstet. Gynaecol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="97" to="110" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Immunology and ovarian cancers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1097/JCMA.0000000000000283</idno>
	</analytic>
	<monogr>
		<title level="j">J. Chin. Med. Assoc</title>
		<imprint>
			<biblScope unit="volume">2020</biblScope>
			<biblScope unit="page" from="425" to="432" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Total and out-of-pocket costs of different primary management strategies in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Suidan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Rauh-Hain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Giordano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Meyer</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ajog.2019.04.005</idno>
	</analytic>
	<monogr>
		<title level="j">Am. J. Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">221</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>e1-136.e9. [CrossRef</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Markman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Wilczynski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Monk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Copeland</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Alberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecologic Oncology Group. Southwest Oncology, Oncology G. Gynecologic</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2460" to="2465" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note>J. Clin. Oncol.</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">E</forename><surname>De Jongh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>De Wit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Verweij</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Sparreboom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Van Den</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Bent</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Stoter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Van Der Burg</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0959-8049(02)00242-3</idno>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: A phase II study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Viret</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Bertucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Genre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Gravis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Chabannon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Conte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Houvenaeghel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Maraninchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Viens</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bmt.1703762</idno>
	</analytic>
	<monogr>
		<title level="j">Bone, Marrow, Transplant</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="879" to="884" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Weekly administration of paclitaxel: Theoretical and clinical basis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Marchetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Urien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">A</forename><surname>Cappellini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Ronzino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Ficorella</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1040-8428(02)00109-9</idno>
		<idno>S3-S13</idno>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Oncol. Hematol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Is one cycle every three or four week&apos;s obsolete? A critical review of dose-dense chemotherapy in solid neoplasms</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fizazi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Zelek</surname></persName>
		</author>
		<idno type="DOI">10.1023/A:1008344014518</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="133" to="149" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">The genetic origin of drug resistance in neoplasms: Implication for systemic therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Goldie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Coldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer. Res</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="3643" to="3653" />
			<date type="published" when="1984" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">The Norton-Simon hypothesis revisited</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Norton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Simon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer. Treat. Rep</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="163" to="169" />
			<date type="published" when="1986" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">The Norton-Simon hypothesis: Designing more effective and less toxic chemotherapeutic regimens</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Norton</surname></persName>
		</author>
		<idno type="DOI">10.1038/ncponc0560</idno>
	</analytic>
	<monogr>
		<title level="j">Nat. Clin. Pract. Oncol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="406" to="407" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Weekly paclitaxel in the adjuvant treatment of breast cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Sparano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Martino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Saphner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">C</forename><surname>Wolff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">W</forename><surname>Sledge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Jr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">C</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">E</forename><surname>Davidson</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0707056</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="1663" to="1671" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<monogr>
		<title level="m" type="main">Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: A retrospective study of feasibility and efficacy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Milani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Kristeleit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mccormack</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Raja</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Luvero</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Widschwendter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Mould</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Olatain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hackshaw</surname></persName>
		</author>
		<idno type="DOI">10.1136/esmoopen-2016-000117</idno>
		<imprint/>
	</monogr>
	<note>ESMO Open 2017, 1, e000117. [CrossRef</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Rettenmaier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Micha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Bohart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">H</forename><surname>Goldstein</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejogrb.2019.10.047</idno>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Obstet. Gynecol. Reprod. Biol</title>
		<imprint>
			<biblScope unit="volume">2020</biblScope>
			<biblScope unit="page" from="101" to="105" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Mahmoudjafari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Bivona</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Grauer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Henry</surname></persName>
		</author>
		<idno type="DOI">10.1177/1078155219899460</idno>
	</analytic>
	<monogr>
		<title level="j">J. Oncol. Pharm</title>
		<imprint/>
	</monogr>
	<note>Pract. 2020, 1078155219899460. [CrossRef. PubMed</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Dose-dense chemotherapy improves mechanisms of antitumor immune response</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">T</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">Z</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">F</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-12-2225</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer. Res</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="119" to="127" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Adherence to hematologic hold parameters in carboplatin and dose-dense paclitaxel chemotherapy for ovarian malignancies: A survey of NCCN member institutions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Stasenko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">K</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Brackman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Mclean</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Uppal</surname></persName>
		</author>
		<idno type="DOI">10.6004/jnccn.2016.0089</idno>
	</analytic>
	<monogr>
		<title level="j">J. Natl. Compr. Cancer Netw</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="849" to="853" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Boraska Jelavić</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Boban</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Brčić</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Vrdoljak</surname></persName>
		</author>
		<idno type="DOI">10.1097/CAD.0000000000000538</idno>
	</analytic>
	<monogr>
		<title level="j">Anticancer Drugs</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="922" to="927" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">S</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Chien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Chang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tjog.2016.04.017</idno>
	</analytic>
	<monogr>
		<title level="j">Taiwan J Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="405" to="409" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Does a simple hematological examination predict the response and side effects in patients undergoing induction chemotherapy and/or neoadjuvant chemotherapy?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">S</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1097/JCMA.0000000000000239</idno>
	</analytic>
	<monogr>
		<title level="j">J. Chin. Med. Assoc</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="107" to="108" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Dose dense&quot; chemotherapy in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Vasey</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1525-1438.2005.00438.x</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Gynecol. Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="226" to="232" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note>Suppl. 3</note>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Sequential single agents as first-line chemotherapy for ovarian cancer: A strategy derived from the results of GOG-132</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">M</forename><surname>Muggia</surname></persName>
		</author>
		<idno type="DOI">10.1136/ijgc-00009577-200311001-00005</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Gynecol. Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="156" to="162" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note>Suppl. 2</note>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">M</forename><surname>Muggia</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.seminoncol.2004.11.024</idno>
	</analytic>
	<monogr>
		<title level="j">Semin. Oncol</title>
		<imprint>
			<biblScope unit="page" from="19" to="24" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
	<note>Suppl. 15</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">What is the role of dose-dense therapy?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Van Der Burg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Van Der Gaast</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Van Doorn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>De Wit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Stoter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Verweij</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1525-1438.2005.00432.x</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Gynecol. Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="233" to="240" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note>Suppl. 3</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Van Den Bent</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Van Putten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Hilkens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>De Wit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Van Der Burg</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0959-8049(01)00381-1</idno>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="387" to="391" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Dose intensity in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Vasey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">B</forename><surname>Kaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">In Ovarian Cancer Controversies in Management</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Gershenson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">P</forename><surname>Mcguire</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Eds</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Churchill Livingstone</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1997" />
			<biblScope unit="page" from="139" to="169" />
			<pubPlace>New York, NY, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Fruscio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Garbi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Parma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Lissoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Garavaglia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Bonazzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Dell'anna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Mangioni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Milani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Colombo</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djq530</idno>
	</analytic>
	<monogr>
		<title level="j">J. Natl. Cancer. Inst</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="347" to="351" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">A</forename><surname>Boere</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Van Der Burg</surname></persName>
		</author>
		<idno type="DOI">10.2174/138161212802002634</idno>
	</analytic>
	<monogr>
		<title level="j">Curr. Pharm. Des</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="3741" to="3753" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: A feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: A Gynecologic Oncology Group study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">D</forename><surname>Tiersten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">W</forename><surname>Sill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Muggia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Swensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">P</forename><surname>Warshal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Mannel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">M</forename><surname>Fracasso</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2010.05.020</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="303" to="307" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Briasoulis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Karavasilis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Tzamakou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Haidou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Piperidou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Pavlidis</surname></persName>
		</author>
		<idno type="DOI">10.1097/00001813-200206000-00006</idno>
	</analytic>
	<monogr>
		<title level="j">Anticancer Drugs</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="481" to="489" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Role of weekly paclitaxel in the treatment of advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Rosenberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1040-8428(02)00103-8</idno>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Oncol. Hematol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="43" to="51" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Kinoshita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hosokawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Honjo</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00280-006-0209-6</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer. Chemother. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="665" to="672" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Dose-dense paclitaxel in advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">J</forename><surname>Hoskins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">V</forename><surname>Tinker</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clon.2014.10.001</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Oncol. (R. Coll. Radiol)</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="40" to="47" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">First-line chemotherapy for ovarian cancer-the controversy continues</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">B</forename><surname>Kaye</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bjc.6600568</idno>
	</analytic>
	<monogr>
		<title level="j">Br. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="813" to="814" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Estimation of renal function in adult outpatients with normal serum creatinine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Fiseha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Mengesha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Girma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kebede</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Gebreweld</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13104-019-4487-6</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Res. Notes</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<monogr>
		<title level="m" type="main">Risks of female genital tract related cancers (gynecological cancers) or breast cancer in women with and without chronic kidney disease: A population-based cohort study in Taiwan</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Horng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1097/MD.0000000000010157</idno>
		<imprint>
			<date type="published" when="2018" />
			<biblScope unit="volume">97</biblScope>
		</imprint>
	</monogr>
	<note>e0157. [CrossRef. PubMed</note>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Endometriosis might be inversely associated with developing chronic kidney disease: A population-based cohort study in Taiwan</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms17071079</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">1079</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute&apos;s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">E</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Shoenbill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">C</forename><surname>Dueck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Schrag</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Bruner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Minasian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>St Germain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>O'mara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Baumgartner</surname></persName>
		</author>
		<idno type="DOI">10.1093/jamia/ocy169</idno>
	</analytic>
	<monogr>
		<title level="j">J. Am. Med. Inform. Assoc</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="276" to="285" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Software for administering the National Cancer Institute&apos;s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">W</forename><surname>Schoen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Basch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">L</forename><surname>Hudson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">E</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">R</forename><surname>Mendoza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>St Germain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Baumgartner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Sit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Rogak</surname></persName>
		</author>
		<idno type="DOI">10.2196/10070</idno>
	</analytic>
	<monogr>
		<title level="j">JMIR Hum. Factors</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">The evaluation of response to immunotherapy in metastatic renal cell carcinoma: Open challenges in the clinical practice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Raimondi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Randon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Sepe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Claps</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Verzoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>De Braud</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Procopio</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms20174263</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">4263</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Guidelines for response criteria for use in trials testing immunotherapeutics</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Seymour</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bogaerts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Perrone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">H</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Mandrekar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">U</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Litière</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Dancey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(17)30074-8</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet. Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="143" to="152" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Radiology workflow for RECIST assessment in clinical trials: Can we reconcile time-efficiency and quality?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Beaumont</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">S</forename><surname>Bertrand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Klifa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Patriti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Cippolini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Lovera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Iannessi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejrad.2019.07.030</idno>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Radiol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="257" to="263" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Weekly dose-dense paclitaxel and triweekly low-dose cisplatin: A well-tolerated and effective chemotherapeutic regimen for first-line treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">R</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Horng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph16234794</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">4794</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">B</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13048-016-0266-3</idno>
	</analytic>
	<monogr>
		<title level="j">J. Ovarian. Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">N</forename><surname>Abaid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Micha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Rettenmaier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">V</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Mendivil</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Lopez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">H</forename><surname>Goldstein</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00280-013-2173-2</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer. Chemother. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="101" to="107" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Tung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">N</forename><surname>Westin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Bhosale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Munsell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">K</forename><surname>Sood</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2017.07.137</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="41" to="46" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Bun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Yunokawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ebata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Shimomura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Shimoi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kodaira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yonemori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Fujiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Kato</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00280-016-3100-0</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer. Chemother. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="745" to="752" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: A retrospective study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Bun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Yunokawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ebata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kobayashi Kato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Shimoi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Tamura</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10147-019-01449-3</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1111" to="1118" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Minagawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kigawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Kanamori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Itamochi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Terakawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Okada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Kitada</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2005.11.020</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="495" to="498" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Morton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">N</forename><surname>George</surname></persName>
		</author>
		<idno type="DOI">10.1200/JOP.2016.012096</idno>
	</analytic>
	<monogr>
		<title level="j">J. Oncol. Pract</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="523" to="530" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Management of thrombocytopenia in cancer patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">V</forename><surname>Mones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Soff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer. Treat. Res</title>
		<imprint>
			<biblScope unit="volume">179</biblScope>
			<biblScope unit="page" from="139" to="150" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Al-Samkari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Connors</surname></persName>
		</author>
		<idno type="DOI">10.1182/bloodadvances.2019000369</idno>
	</analytic>
	<monogr>
		<title level="j">Blood Adv</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="3770" to="3779" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Carboplatin/paclitaxel induction in ovarian cancer: The finer points</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">R</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">M</forename><surname>Muggia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="418" to="420" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Egorin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">A</forename><surname>Van Echo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Tipping</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Olman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Y</forename><surname>Whitacre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">W</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Aisner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer. Res</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="5432" to="5438" />
			<date type="published" when="1984" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">Y</forename><surname>Shyong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">C</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Y</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Yen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">T</forename><surname>Ng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Zhonghua Yi Xue Za Zhi (Taipei)</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="220" to="225" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Optimal primary surgical treatment for advanced epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Elattar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bryant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">A</forename><surname>Winter-Roach</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hatem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Naik</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.CD007565.pub2</idno>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst. Rev</title>
		<imprint>
			<biblScope unit="volume">007565</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Javellana</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Hoppenot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Lengyel</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2018.11.007</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="228" to="234" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Moving beyond &quot;complete surgical resection&quot; and &quot;optimal&quot;: Is low-volume residual disease another option for primary debulking surgery?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Manning-Geist</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hicks-Courant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Gockley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">G</forename><surname>Del Carmen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">B</forename><surname>Growdon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">S</forename><surname>Horowitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Berkowitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">G</forename><surname>Muto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Worley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Jr</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2018.06.015</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="233" to="238" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">D</forename><surname>Sioulas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">B</forename><surname>Schiavone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Kadouri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Zivanovic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Roche</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>O'cearbhaill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">R</forename><surname>Abu-Rustum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">A</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Sonoda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">J</forename><surname>Gardner</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2017.02.023</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="15" to="20" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">The improved effects of a multidisciplinary team on the survival of breast cancer patients: Experiences from China</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Ying</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph17010277</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">277</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Environmental exposures during puberty: Window of breast cancer risk and epigenetic damage</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Natarajan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Aljaber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Au</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Thai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Nunez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Resto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Chavez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Benmarhnia</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph17020493</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">493</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Targeted transdermal delivery of curcumin for breast cancer prevention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Atlan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Neman</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph16244949</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">4949</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">The cost-effectiveness analysis of cervical cancer screening using a systematic invitation system in Lithuania</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Paulauskiene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Stelemekas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Ivanauskiene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Petkeviciene</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph16245035</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">Improving screening uptake among breast cancer survivors and their first-degree relatives at elevated risk to breast cancer: Results and implications of a randomized study in the state of Georgia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Lipscomb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Escoffery</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">W</forename><surname>Gillespie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Henley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Chociemski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Almon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Goodman</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph17030977</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">977</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Harano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Terauchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Katsumata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Yasuda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Takakura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Takano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Sugiyama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann. Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="251" to="257" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Dalton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Kapp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">J</forename><surname>Monk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">K</forename><surname>Chan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2011.09.028</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="199" to="204" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Seagle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Shahabi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2017.02.014</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="9" to="14" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">Dose dense chemotherapy for front-line ovarian cancer treatment: The price is right?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Herzog</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Cohn</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2017.03.001</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">ASCO value framework highlights the relative value of treatment options in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Foote</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Secord</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Cohn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Jewell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Havrilesky</surname></persName>
		</author>
		<idno type="DOI">10.1200/JOP.2017.025106</idno>
	</analytic>
	<monogr>
		<title level="j">J. Oncol. Pract</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1030" to="1039" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Y</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">M</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">I</forename><surname>Tergas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">V</forename><surname>Ananth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">I</forename><surname>Neugut</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Hershman</surname></persName>
		</author>
		<idno type="DOI">10.1097/AOG.0000000000001436</idno>
	</analytic>
	<monogr>
		<title level="j">Obstet. Gynecol</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="985" to="991" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
